Induction of Apoptosis by Yomogin in Human Promyelocytic Leukemic HL-60 Cells
plates were incubated for an additional 4 h. The medium was discarded and the formazan blue formed in the cells was dissolved with DMSO 100 ml. The optical density was measured at 540 nm.
Trypan Blue Assay HL-60 human promyelocytic leukemia cells were cultured in RPMI 1640 medium with 10% FBS in a CO 2 incubator at 37°C in the presence or absence of chemicals. Cells were seeded at a concentration of 2ϫ10 5 cells/ml, maintained at logarithmic growth by passaging them every 2-3 d, and incubated for 1-4 d with yomogin at various concentrations. Yomogin dissolved in DMSO was added to medium in serial dilutions (the final DMSO concentration in all assays did not exceed 0.1%). Cell viability was checked using the trypan blue dye-exclusion method.
Detection and Quantification of DNA Fragmentation Genomic DNA was prepared for gel electrophoresis as previously described. 8) Electrophoresis was performed in a 1.5% (w/v) agarose gel in 40 mM Tris-acetate buffer (pH 7.4) at 50 V for 1 h. The fragmented DNA was visualized by staining with ethidium bromide after electrophoresis. DNA fragmentation was quantitated as previously reported. 8) In brief, cells were lysed in a solution containing 5 mM Tris-HCl (pH 7.4), 1 mM EDTA, and 0.5% (w/v) Triton X-100 for 20 min on ice. The lysate and supernatant after centrifugation at 27000ϫg for 20 min were sonicated for 40 s, and the level of DNA in each fraction was measured with a fluorometric method using DAPI. The amount of the fragmented DNA was calculated as the ratio of the amount of DNA in the supernatant to that in the lysate.
Apoptosis Assessment by Annexin-V Staining At the end of the various treatment periods, the cells were washed twice with PBS and resuspended in 100 ml of staining solution containing annexin-V fluorescein and propidium iodide (PI) in HEPES buffer. The cell suspensions were incubated for 15 min at room temperature, followed by flow cytometer analysis of 20000 cells in each group. Annexin-V binds to cells that express phosphatidylserine on the outer layer of the cell membrane. This allow for the discrimination of living cells (unstained with either fluorochrome) from apoptotic cells (stained only with annexin-V) and necrotic cells (stained with both annexin-V and PI). Data analysis was performed with the standard Cell Quest software.
Preparation of Cytosolic and Mitochondrial Fractionation and Western Blot Analysis HL-60 cells (2.5ϫ10 7 ) were collected by centrifugation at 200ϫg for 10 min at 4°C. The cells were washed twice with ice-cold PBS, pH 7.2, followed by centrifugation at 200ϫg for 5 min. The cell pellet was then resuspened in ice-cold cell extraction buffer (20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, PMSF 100 mM, protease inhibitor cocktail) for 30 min on ice. Cells were then homogenized with a glass Dounce B-type pestle (80 strokes) and subjected to centrifugation at 1000ϫg to remove unbroken cells, pellet nuclei, and heavy membranes. The postnuclear supernatant was centrifuged at 14000ϫg for 30 min to yield a pellet mitochondria-enriched heavy membrane fraction, and the resulting supernatant was further centrifuged at 100000ϫg to obtain the cytosolic fraction. Supernatants were then frozen in aliquots at Ϫ70°C until required. The mitochondria-rich fraction was washed once with extraction buffer, followed by a final resuspension in lysis buffer [150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% NP40, 0.25% sodium deoxycholate, and 1 mM EGTA] containing protease inhibitors. Approximately 40 mg of cytosolic or mitochondrial protein extracts were separated using 15% SDS-polyacrylamide gels and transferred to nitrocellulose. The blots were incubated with monoclonal anti-cytochrome c, anti-Bax, anti-Bcl-2, anti-Bcl-xL, polyclonal anti-Bid, and anti-caspase-3, -8, and -9 antibodies followed by enhanced chemiluminescence (ECL)-based detection (Amersham Pharmacia Biotech).
Measurement of Mitochondrial Membrane Potential and Cell Death After treatment with yomogin (20 mM), HL-60 cells were collected and washed with PBS. Resuspended cells in 0.5 ml of PBS were incubated in the dark with 40 nM DiOC 6 and PI 50 mg/ml for 15 min and analyzed using the FACScater-plus Flow cytometer.
Data Analysis Data are reported as mean valuesϮS.D. of three independent determinations. All experiments were done at least three times, with three or more independent observations each time. Statistical analysis was performed using Student's t-test.
RESULTS

Cell Growth Inhibition
We initiated our study by examining the cytotoxic effects of yomogin using the MTT assay in various leukemia cells. Yomogin showed different degrees of cytotoxicity in these cells as judged by the IC 50 values, which ranged from 4.2 to 18.5 mM (Table 1) . Among the tested leukemia cell lines, HL-60 cells were the most vulnerable to yomogin. The effects of yomogin on the viability of HL-60 cells were also examined. The viability of HL-60 cells was inhibited in a concentration-and time-dependent manner ( Fig. 1B) , suggesting that this chemical has antiproliferative activity.
Induction of Apoptosis by Yomogin
The induction of DNA fragmentation was demonstrated by incubating HL-60 cells with different concentrations of yomogin for various times. The amount of fragmented DNA, quantified by a fluorometric method using DAPI, gradually increased in a timeand concentration-dependent manner ( Fig. 2A) , and a ladder pattern of internucleosomal fragmentation of DNA was apparent when cells were treated with yomogin 20 mM for 20 h (Fig. 2B ). To characterize yomogin-induced apoptosis further, we performed a biparametric cytofluorimetric analysis using PI and annexin V-FITC, which stain DNA and phosphatidylserine residues, respectively. As indicated in a) IC 50 is defined as the concentration which results in a 50% decrease in cell number as compared with that of the control cultures in the absence of an inhibitor. The values represent the mean of three independent experiments.
centage of annexin V-and PI-positive cells (late stages of apoptosis and/or dead cells) reached about 75%. These results indicate that yomogin induced apoptotic cell death in HL-60 cells.
Requirement for Caspase Activities during YomoginInduced Apoptosis
Since it has been suggested that apoptosis requires the activation of caspases, 9) we investigated the involvement of caspase activation in yomogin-induced apoptosis in HL-60 cells using Western blot analysis to analyze the activation of various caspases. Treatment of cells with yomogin 20 mM caused proteolytic cleavages of procaspase-8, procaspase-9, and procaspase-3 in a time-dependent manner (Fig. 3A) . To determine whether the activation of caspase-8 and caspase-3 is required for the induction of cell death by yomogin, we pretreated HL-60 cells with caspase inhibitors. As shown in Fig. 3B , z-VAD-fmk (a general caspase inhibitor), z-IETD-fmk (a caspase-8 inhibitor), and z-DEVDfmk (a caspase-3 inhibitor) markedly attenuated yomoginstimulated DNA fragmentation. Thus these data suggest that yomogin-induced apoptotic cell death is largely dependent on caspase activation.
Yomogin Induces Caspase-8-Dependent Bid Cleavage, Bax Translocation, and Cytochrome c Release To evaluate the contribution of the mitochondrial pathway to the induction of apoptosis after yomogin treatment, we examined changes in cytochrome c release into the cytosol and mitochondrial membrane potential in yomogin-treated leukemia cells. Figure 4A shows that yomogin treatment significantly increased the level of cytosolic cytochrome c, whereas its level in mitochondria concomitantly decreased. Release of cytochrome c into the cytosol is usually preceded or accompanied by a drop in the mitochondrial membrane potential Dy m . To evaluate the mitochondrial membrane potential in yomogin-induced apoptosis, we stained the cells with DiOC 6 and PI (Fig. 4B) . CCCP induced depolarization of Dy m , but in the yomogin-treated HL-60 cells, the proportion of Dy m depolarized cells in the lower left quadrant was not increased in spite of cell death progression. These data indicate that the cytochrome c which was released without Dy m depolarization contributed to yomogin-induced apoptosis of HL-60 cells.
Caspase-8 has been reported to cleave Bid after treatment with chemotherapeutic agents, 10) and then the truncated Bid (tBid) triggers the mitochondrial release of cytochrome c into the cytosol and activates caspase-9. To investigate whether caspase-8 activation caused by yomogin precedes cytochrome c release, we examined the kinetics of Bid cleavage after yomogin treatment. Figure 4A shows that yomogin caused time-dependent Bid cleavage, coinciding with the changes in caspase-8 activation in HL-60 cells, suggesting that Bid is involved in cytochrome c release after yomogin treatment. Because it has been shown that tBid, which translocates to mitochondria during apoptosis, was able to trigger a change in Bax conformation, 11) cytochrome c release, and subsequent caspase activation, we further investi- A, Yomogin caused the cleavage of procaspase-8, -9, and -3 in cytosol. HL-60 cells were treated with yomogin (20 mM) for indicated times. After treatment, the cytosolic fractions were separated by SDS-PAGE, transferred to cellulose membranes, and then blotted with caspase-8-, caspase-9-, and caspase-3-specific antibodies. The amount of b-actin was measured as an internal control. B, Effect of caspase inhibitors (z-VADfmk, z-DEVD-fmk, and z-IETD-fmk) on apoptosis in response to yomogin-induced DNA fragmentation. HL-60 cells were pretreated with and without z-DEVD-fmk 50 mM, z-VAD-fmk 50 mM, and z-IETD-fmk 50 mM for 1 h, and then challenged with yomogin 20 mM for 20 h. DNA fragmentation was measured using DAPI as described in Materials and Methods. ᮀ, None; , yomogin. Data presented are the meanϮS.D. of results from three independent experiments. * pϽ0.01, significantly different from the yomogin-treated group by Student's t-test. Figure 4A shows that yomogin treatment (20 mM) dramatically redistributed Bax from cytosol to the mitochondria. In addition, the level of antiapoptotic Bcl-2 was slightly decreased in a time-dependent manner after yomogin treatment.
To determine whether translocation of Bid and Bax proteins occurs in a caspase-8-dependent manner, we examined the effect of z-IETD-fmk (caspase-8 inhibitor) on yomogininduced Bid and Bax translocation and cytochrome c relaease. Pretreatment with caspase-8 inhibitor completely prevented the yomogin-induced intracellular Bid and Bax translocation and cytochrome c release (Fig. 4C) . These results suggest that yomogin induces translocation of the Bid and Bax proteins to the mitochondria in a caspase-8-dependent manner during the progression of apoptosis.
DISCUSSION
An imbalance between cell proliferation, apoptosis, and differentiation leads to the development of clones of malignant cells. Based on the understanding of tumor biology in respect of the kinetics of cell populations, two new strategies, induction of differentiation and apoptosis, have recently emerged in the fields of cancer chemoprevention and chemotherapy. The search for new chemopreventive and antitumor agents that are more effective and less toxic has created a great deal of interest in phytochemicals. In this respect, sesquiterpene lactones are compounds of natural origin and are known to have cytotoxic effects. 12, 13) Although it has recently been reported that yomogin (0.25-2 mM) synergistically enhances differentiation of HL-60 cells when combined with 5 nM 1,25-dihydroxyviatmin D 3 or 50 nM all-trans retinoic acid, 14) its molecular mechanisms and apoptosis-inducing effects are not known. The present results demonstrate for the first time that yomogin can induce apoptosis in human leukemia cells. This effect of yomogin was confirmed by the DNA fragmentation assay, DNA ladder formation on agarose gel electrophoresis, and the loss of membrane asymmetry (Fig. 2) .
One of the early events that initiate apoptosis is the release of cytochrome c from the mitochondria into the cytosol. 2) Consistent with these results, in the cytosol of yomogintreated HL-60 cells, cytochrome c was detected after 2.5-h treatment (Fig. 4A) . Once released into the cytosol, cytochrome c binds to Apaf-1 and procaspase-9 in the presence of deoxyATP or ATP to form the apoptosome. 15) This complex activates caspase-9, which in turn cleaves and thereby activates caspase-3. In the yomogin-treated cells, release of cytochrome c from the mitochondria was followed by activation of csapase-9 and -3 (Fig. 3A) . Pretreatment with the general caspase inhibitor z-VAD-fmk, specific caspase-8 inhibitor z-IETD-fmk, and specific caspase-3 inhibitor z-DEVD-fmk completely prevented yomogin-induced DNA fragmentation (Fig. 3B) , suggesting that apoptosis induced by yomogin involves a caspase-8-and caspase-3-mediated mechanism. Taken together, our data suggest a specific activation of caspase-8 and caspase-3. Although we observed that yomogin caused the activation of caspase-8, we failed to detect changes in the expression of death receptors (DRs) (Fas, DR4, DR5, and TNFR1), or in the interaction between FADD and caspase-8 (results not shown). This suggests that yomogin-mediated caspase-8 activation and apoptosis are independent of DRs and/or FADD. It has recently been reported that anticancer drugs induce apoptosis and caspase-8 cleavage in a FADD-independent manner, suggesting that DR activation is not prerequisite for drug-induced caspase-8 activation. 16) The mechanism of capase-8 processing and activation independently of DRs is intriguing. In addition to the DR/FADD pathway, it has recently become clear that a second, either independent or interconnected, pathway exists, which is essentially controlled by the release of mitochondrial components and inhibited by antiapoptotic members of the Bcl-2 family. 17, 18) Caspase-8 activity is often responsible for mitochondrial translocation of Bid, which plays key roles in processes underlying programmed cell death. Our results indicate that yomogin can induce cleavage of the proapoptotic protein Bid. Both caspase-8 and granzyme B are known to cleave the Bid protein. 19, 20) Thus it is likely that yomogin first activates caspase-8, which leads to cleavage of Bid. Bid has been reported to translocate from the cytoplasm to the mitochondria and induce cytochrome c release, 19) and we found that tBid translocates and integrates in the mitochondrial membrane during yomogin-induced apoptosis. Therefore we speculate that the induction of apoptosis observed in this study may reflect a distinct mechanism for the chemopreventive function of yomogin.
Bax is found in the cytosol and is constitutively present in many cell types that undergo apoptosis in response to a variety of stimuli. Bax translocation to the mitochondria has been shown to reduce the mitochondrial membrane potential (MMP), enhance cytochrome c release from the mitochondria, and activate caspases. 21) In contrast, Bcl-2 prevents the release of cytochrome c in cells. Our data show that yomogin induced Bax translocation from the cytosol to the mitochondria, rendered Bcl-2 unable to heterodimerize with Bax, and then cytochrome c was released into the cytosol without changing the MMP. Furthermore, the caspase-8-specific inhibitor z-IETD-fmk inhibited these events, strongly suggesting that yomogin-induced Bax translocation and cytochrome c release from the mitochondria are associated with caspase-8 activation.
Carcinogens usually cause genomic damage in the exposed cells. As a consequence, the damaged cells may be triggered either to undergo apoptosis or to proliferate with genomic damage, leading to the formation of cancerous cells that generally exhibit cell cycle abnormalities. 22, 23) Thus the ability of yomogin alone to induce apoptosis suggests its potential use as a chemopreventive agent because many anticancer drugs are known to exert their antitumor function by inducing apoptosis in the target cells.
Compounds capable of inducing apoptosis of human cancer cells have recently attracted a great deal of attention due to their potential utilization as anticancer agents, and many known chemopreventive agents exert their anticancer effects by inducing apoptosis of cancer cells. 24) In the present study, we demonstrated that yomogin, a natural compound isolated from the A. princep PALPAN, induces apoptosis of human cancer cells, and we are now investigating whether yomogin can be further developed into a chemopreventive agent.
